Better Innovations

Better Living Through Innovation

  • Wellness
  • Health
  • Exercise
  • Therapy
    • Back Pain
  • Funny

COST OF NEW CANCER DRUG CUT IN HALF AFTER REJECTION FROM SLOAN-KETTERING

November 13, 2012 By Angela

Zaltrap,one of the newest cancer fighting drugs, came to market in August at a pricetag to doctors and hospitals of about $11,000 a month. Soon after, Memorial Sloan-Kettering Cancer Center in New York decided not to use the drug, citing the increased cost and similar effectiveness with a similar medicine, Avastin from Genentech as the reason. Sanofi, the drug’s manufacturer, announced that it was cutting the cost in half in response to the large cancer center’s decision. One can only wonder if this is the beginning of a new trend in medical treatment; considering the overall effectiveness with respect to the cost when other drugs perform just as well with a decreased pricetag.

 

 

Click to Share:

  • Click to share on Facebook (Opens in new window)
  • Click to share on Twitter (Opens in new window)
  • Click to share on Reddit (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • More
  • Click to share on LinkedIn (Opens in new window)
  • Click to print (Opens in new window)

Filed Under: News and Information Tagged With: Avastin, cancer drug, cancer treatment, Zaltrap

Follow Us on FacebookFollow Us on Google+Follow Us on TwitterFollow Us on YouTubeFollow Us on RSS
Get UNLIMITED Personal Support ABSOLUTELY FREE for 90 Days!

Popular Posts

  • Review: Weider X-Factor Home Gym – Door Mounted
  • Comparison Review: Comparing PowerLung with…
  • Best Before Bed Snacks To Keep You Lean
  • Motivational Health, Wellness, and Fitness Quotes
  • Review: DPL Therapy System – Deep Penetrating…
  • DPL Nuve Handheld Light Therapy System Review
  • Needak vs. Reboundair Rebounders – Comparison

About Us

Blog Archive

Privacy Policy

Disclaimer

Disclosure

Contact Us

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.